Stevens Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Stevens Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,860	Closed	-$205K	–	327
2024 Q4	$205K	Buy	+5,860	New	+$219K	0.08%	309
2019 Q3	–	Sell	-8,742	Closed	-$562K	–	652
2019 Q2	$562K	Buy	+8,742	New	+$618K	0.03%	450
2018 Q3	–	Sell	-47,586	Closed	-$1.98M	–	841
2018 Q2	$1.98M	Buy	47,586 +20,661	+77%	+$916K	0.07%	313
2018 Q1	$1.19M	Buy	+26,925	New	+$1.37M	0.05%	378
2017 Q4	–	Sell	-13,151	Closed	-$667K	–	929
2017 Q3	$667K	Buy	+13,151	New	+$689K	0.02%	503
2017 Q2	–	Sell	-45,634	Closed	-$1.83M	–	949
2017 Q1	$1.83M	Buy	+45,634	New	+$2.05M	0.07%	319
2015 Q4	–	Sell	-24,421	Closed	-$987K	–	1016
2015 Q3	$987K	Sell	24,421 -21,329	-47%	-$1.1M	0.05%	361
2015 Q2	$2.63M	Buy	45,750 +40,633	+794%	+$2.58M	0.09%	235
2015 Q1	$326K	Buy	+5,117	New	+$347K	0.01%	718
2014 Q3	–	Sell	-8,600	Closed	-$296K	–	1119
2014 Q2	$296K	Buy	8,600 +2,084	+32%	+$65.6K	0.01%	815
2014 Q1	$282K	Buy	+6,516	New	+$316K	0.01%	809

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stevens Capital Management's IONS Position: Q1 2025 in Review

Stevens Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 5,860 shares — an estimated $205K sold.

Stevens Capital Management first reported a position in IONS in Q1 2014 and held it in 11 quarters. The position peaked at $2.63M in Q2 2015. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.

Stevens Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Stevens Capital Management sold 5,860 Ionis Pharmaceuticals shares in Q1 2025, an estimated $205K.
Stevens Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Stevens Capital Management's Ionis Pharmaceuticals position peaked at $2.63M in Q2 2015.
343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.

Based on Stevens Capital Management's 13F filing for Q1 2025, filed 7 May 2025.